APOE and Alzheimer disease: It is important to note that the introduction of human APOE3 and APOE4 into transgenic mice expressing familial AD mutations has been reported to distinctly delay Aβ deposition in young animals [52,74] and, opposite to humans, is usually observed in older ages [33,50,75], where, once detected, plaque levels are higher with APOE4 than with APOE3, in concordance with our current findings.